Sutro Biopharma (STRO) Current Leases (2021 - 2025)

Sutro Biopharma has disclosed Current Leases across 5 years of filings, most recently posting $7.8 million for Q4 2025.

• Current Leases for Q4 2025 came in at $7.8 million, up 4.05% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.8 million (up 4.05% YoY), and the FY2025 annual result was $7.8 million, up 4.05% from the prior year.
• Current Leases came in at $7.8 million for Q4 2025 at Sutro Biopharma, down from $8.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $8.1 million in Q2 2025 to a low of $1.0 million in Q4 2021.
• The 5-year median for Current Leases is $6.3 million (2023), against an average of $5.3 million.
• Across the five-year window, Current Leases surged 429.82% in 2023 and increased 4.05% in 2025, its largest moves.
• Sutro Biopharma's Current Leases stood at $1.0 million in 2021, then surged by 342.14% to $4.6 million in 2022, then surged by 40.02% to $6.4 million in 2023, then climbed by 16.51% to $7.5 million in 2024, then advanced by 4.05% to $7.8 million in 2025.
• The last three Current Leases figures came in at $7.8 million (Q4 2025), $8.0 million (Q3 2025), and $8.1 million (Q2 2025), per Business Quant data.